Top

Published in:

01-12-2012 | Research Article

Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma

Authors: Takeshi Hanagiri, Shinji Shinohara, Masaru Takenaka, Yoshiki Shigematsu, Manabu Yasuda, Hidehiko Shimokawa, Yoshika Nagata, Makoto Nakagawa, Hidetaka Uramoto, Tomoko So, Fumihiro Tanaka

Published in: Tumor Biology | Issue 6/2012

Abstract

Hyaluronic acid (HA) has been proposed as a biochemical marker of malignant pleural mesothelioma (MPM). The present study focused on the implications of HA and CD44 interaction in the proliferation and invasiveness of MPM. The proliferation and invasive activity was evaluated in two human mesothelioma cell lines, ACC-MESO-1 and K921MSO, by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and the transwell chamber model. The knockdown of CD44 gene expression was accomplished by transfection of the cells with small interfering RNA. Flow cytometry revealed that both the ACC-MESO-1 and K921MSO cell lines highly expressed CD44. Treatment with HA enhanced the proliferation in both mesothelioma cell lines in comparison to cells without HA treatment. The treatment with HA (25 μg/ml) also significantly upregulated the invasion of both types of cells. The silencing of CD44 significantly abrogated the effect of HA treatment on the proliferation of ACC-MESO-1 cells and significantly suppressed the proliferation of K921MSO cells. HA–CD44 binding is important for the migration and proliferation of mesothelioma cells. Therefore, the HA–CD44 interaction is a potentially useful therapeutic target in MPM.

Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–9.PubMedCrossRef

Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–72.PubMedCrossRef

Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci. 2012;103:483–90.PubMedCrossRef

Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49:1–7.PubMedCrossRef

Marinaccio A, Scarselli A, Binazzi A, et al. Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level. Int Arch Occup Environ Health. 2008;81:993–1001.PubMedCrossRef

Maule MM, Magnani C, Dalmasso P, Mirabelli D, Merletti F, Biggeri A. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect. 2007;115:1066–71.PubMedCrossRef

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRef

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506–12.PubMedCrossRef

Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.PubMedCrossRef

10.

Thylén A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001;92:1224–30.PubMedCrossRef

11.

Hillerdal G, Lindqvist U, Engström-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer. 1991;67:2410–4.PubMedCrossRef

12.

Laurent TC, Laurent UB, Fraser JR. Functions of hyaluronan. Ann Rheum Dis. 1995;54:429–32.PubMedCrossRef

13.

Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.PubMedCrossRef

14.

Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97:387–94.PubMedCrossRef

15.

Shigematsu Y, Hanagiri T, Kuroda K, Baba T, Mizukami M, Ichiki Y, et al. Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers. Cancer Sci. 2009;100:1326–34.PubMedCrossRef

16.

Baas P, Schouwink H, Zoetmulder FA. Malignant pleural mesothelioma. Ann Oncol. 1998;9:139–49.PubMedCrossRef

17.

Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007;450:455–61.PubMedCrossRef

18.

Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: an overview. Immunol Cell Biol. 1996;74:A1–7.PubMedCrossRef

19.

Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem. 2004;279:18679–87.PubMedCrossRef

20.

Li Y, Li L, Brown TJ, Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer. 2007;120:2557–67.PubMedCrossRef

21.

Twarock S, Tammi MI, Savani RC, Fischer JW. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem. 2010;285:23276–84.PubMedCrossRef

22.

Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol. 2011;178:956–63.PubMedCrossRef

23.

Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P. Hyaluronan–CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase Cε–Ca²⁺ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem. 2006;281:14026–40.PubMedCrossRef

24.

Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol. 2009;129:1321–4.PubMedCrossRef

25.

Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95(12):930–5.PubMedCrossRef

26.

Goebeler M, Kaufmann D, Bröcker EB, Klein CE. Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci. 1996;109:1957–64.PubMed

27.

Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem. 2000;275:14939–48.PubMedCrossRef

28.

Richter U, Wicklein D, Geleff S, Schumacher U. The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol. 2012;137:687–95.PubMedCrossRef

29.

Li CZ, Liu B, Wen ZQ, Li HY. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol. 2008;54:180–6.

30.

Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861–8.PubMedCrossRef

31.

Sohara Y, Ishiguro N, Machida K, Kurata H, Thant AA, Senga T, et al. Hyaluronan activates cell motility of v-Src-Transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide3-kinase-Akt in a tumor-specific manner. Mol Biol Cell. 2001;12:1859–68.PubMed

Title: Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma
Authors: Takeshi Hanagiri
Shinji Shinohara
Masaru Takenaka
Yoshiki Shigematsu
Manabu Yasuda
Hidehiko Shimokawa
Yoshika Nagata
Makoto Nakagawa
Hidetaka Uramoto
Tomoko So
Fumihiro Tanaka
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0473-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

CD74: a potential novel target for triple-negative breast cancer

Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer

Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway

The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer

The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents

Progesterone receptor (PR) variants exist in breast cancer cells characterised as PR negative

Keynote webinar | Spotlight on antibody–drug conjugates in cancer